Jaktinib

Jaktinib
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-(cyanomethyl)-4-{2-[4-(3,3,5,5-tetradeuteriomorpholin-4-yl)anilino]pyrimidin-4-yl]}benzamide;
CAS Number	1619927-66-0;
DrugBank	DB17545;
UNII	5W59S33KC9;
Chemical and physical data
Formula	C23H18D4N6O2
Molar mass	418.491 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [2H]C1([2H])COCC([2H])([2H])N1c1ccc(Nc2nccc(-c3ccc(C(=O)NCC#N)cc3)n2)cc1;
	InChI InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)/i13D2,14D2; Key:ZVHNDZWQTBEVRY-RYIWKTDQSA-N;

Jaktinib (also known as gecaxitinib) is a Janus kinase inhibitor under development for myelofibrosis.^[1]^[2] It is a deuterated analog of momelotinib.^[1]

References

1 2 Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie (December 2022). "Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial". American Journal of Hematology. 97 (12): 1510–1519. doi:10.1002/ajh.26709. ISSN 1096-8652. PMC 10092883. PMID 36054786.
↑ Zhang, Yi; Zhou, Hu; Xiao, Zhi-Jian; Duan, Minghui; Gao, Sujun; He, Guangsheng; Jing, Hongmei; Li, Junmin; Ma, Liangming; Zhu, Huanling; Chang, Chunkang; Du, Xin; Hong, Mei; Li, Xin; Liu, Qingchi; Wang, Wei; Xu, Na; Yang, Haiping; Zhao, Qingwei; Jin, Jie (2023). "Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study". Journal of Clinical Oncology. 41 (16_suppl): 7061. doi:10.1200/JCO.2023.41.16_suppl.7061.